The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK

Antiviral Therapy

Volumn 17, Issue 4, 2012, Pages 599-603

  Donegan, Katherine L ^a   Walker, A Sarah ^a   Dunn, David ^a   Judd, Ali ^a   Pillay, Deenan ^b   Menson, Esse ^c   Lyall, Hermione ^d   Tudor Williams, Gareth ^d   Gibb, Diana M ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c EVELINA LONDON CHILDREN S HOSPITAL   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; DARUNAVIR PLUS RITONAVIR; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TIPRANAVIR;

ARTICLE; CHILD; DRUG EXPOSURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; POISSON DISTRIBUTION; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; SCORING SYSTEM; UNITED KINGDOM; VIREMIA; VIRUS MUTATION;

ANTI-HIV AGENTS; CHILD; DRUG RESISTANCE, VIRAL; GREAT BRITAIN; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; PREVALENCE; SULFONAMIDES;

EID: 84861657940     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2015     Document Type: Article

References (15)

1. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs lopinavir/ritonavir in treatmentnaive, HIV-1-infected patients: 96-week analysis. AIDS 2009; 23:1679-1688.
2. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITIAN: a randomised controlled Phase III trial. Lancet 2007; 370:49-58. (Pubitemid 47023100)
3. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169-1178. (Pubitemid 46541620)
4. Blanche S, Bologna R, Cahn P, et al. Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatmentexperienced children and adolescents. AIDS 2009; 23:2005-2013.
5. PENTA Steering Committee. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med 2009; 10:591-613.
6. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection; pp. 1-219. (Updated 16 August 2010. Accessed 6 December 2010.) Available from http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf
7. PREZISTA® (darunavir). Summary of product characteristics. (Updated August 2010. Accessed 31 October 2010.) Available from http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR---Product-Information/human/000707/WC500041756. pdf
8. Violari A, Bologna R, Kimutai R, et al. ARIEL: 24-week safety and efficacy of DRV/r in treatment-experienced 3 to <6 year old patients. 18th Conference on Retroviruses and Opportunistic Infection. 27 February-11 March 2011, Boston, MA, USA. Poster 713.
9. de Meyer S, Vangeneugden T, Van Baelen B, et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses 2008; 24:379-388. (Pubitemid 351457745)
10. de Meyer S, Dierynck I, Lathouwers E, et al. Phenotypic and genotypic determinants of resistance to darunavir: analysis of data from treatment experienced patients in POWER 1, 2, 3 and DUET-1 and 2. Antivir Ther 2009; 13 Suppl3:A33.
11. De La Rosa G, Pattery T, Picchio G, Lathouwers E, Villacian J, Van der Borght K. Changing prevalence of darunavir resistance-associated mutations (DRV RAMs) in clinical samples received for routine resistance testing: 2003-2009. 10th International Congress on Drug Therapy in HIV Infection. 7-11 November 2010, Glasgow, UK. Poster P132.
12. de Meyer S, Descamps D, Van Baelen B, et al. Confirmation of the negative impact of protease mutations I47V, I54M, T74P AND I84V and the positive impact of protease mutation V82A on virological response to darunavir/ritonavir. Antivir Ther 2009; 14 Suppl 1:A147.
13. Judd A, Doerholt K, Tookey PA, et al. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care. Clin Infect Dis 2007; 45:918-924. (Pubitemid 47580389)
14. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2010; 18:156-163.
15. Pillay D, Green H, Matthias R, et al. Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J Infect Dis 2005; 192:967-973. (Pubitemid 41266792)